Doxorubicin hydrochloride is approved for use with other drugs as adjuvant therapy for breast cancer that has spread to the lymph nodes, including cancer that is HER-2 positive or has spread after surgery.
In addition to the uses that have been approved by the FDA, doxorubicin hydrochloride is sometimes used alone or with other drugs to treat other types of cancer. The drug continues to be studied in the treatment of many types of cancer.
Men seem to have worse chemotherapy-induced cardiomyopathy than women despite receiving similar cancer treatments, according to research presented today at EuroCMR 2017.
For the first time, WSU researchers have demonstrated a way to deliver a drug to a tumor by attaching it to a blood cell. The innovation could let doctors target tumors with anticancer drugs that might otherwise damage healthy tissues.
Patients with double hit lymphoma (DHL) who undergo autologous stem-cell transplantation (autoSCT) after achieving remission are not more likely to remain in remission or live longer than patients who do not undergo autoSCT, according to a new analysis from the Perelman School of Medicine and the Abramson Cancer Center of the University of Pennsylvania.
The third annual Cardiovascular Tissue Engineering Symposium met at the University of Alabama at Birmingham last month, a gathering of noted physicians and scientists who share the goal of creating new tissues and new knowledge that can prevent or repair heart disease and heart attacks.
A short-term fast appears to counteract increases in blood sugar caused by common cancer drugs and protect healthy cells in mice from becoming too vulnerable to chemotherapy, according to new research from the University of Southern California.
Chemists at the University of Alabama at Birmingham have designed triple-threat cancer-fighting polymer capsules that bring the promise of guided drug delivery closer to preclinical testing.
A team of researchers led by Alex Toker of the Ludwig Center at Harvard has discovered a metabolic weakness in triple-negative breast cancer cells that may be exploited to quell their resistance to chemotherapy.
Wilfried Weber, Professor of Synthetic Biology at the University of Freiburg, has received a grant of roughly €150,000 for his project "Hide and Seek with Cancer Drugs" in which he is working to improve the drugs used in cancer treatment
The time of day that breast cancer chemotherapy drugs are given affects the amount of damaging inflammation in the body, a new study in mice suggests.
Standard chemotherapy is a blunt force instrument against cancer - and it's a rare cancer patient who escapes debilitating side effects from systemic treatments that mostly affect dividing cells, both malignant and healthy, throughout the body.
A team of researchers led by Biomedical Engineering Professor Columbia Engineering has developed a way to manufacture microscale-sized machines from biomaterials that can safely be implanted in the body.
The first data on rare sarcomas in Asian patients is presented in three studies today at the ESMO Asia 2016 Congress in Singapore.
A Japanese research team has become the first in the world to discover that 2-aminobutyric acid (2-AB) is closely involved in the metabolic regulation of the antioxidant glutathione, and that it can effectively raise levels of glutathione in the body when ingested.
A Japanese research team has become the first in the world to discover that 2-aminobutyric acid (2-AB) is closely involved in the metabolic regulation of the antioxidant glutathione, and that it can effectively raise levels of glutathione in the body when ingested. The findings were published in the online version of Scientific Reports on November 9.
There are approximately 15,000 sarcoma cases annually in the United States, comprising more than 60 types of soft tissue sarcomas and 20 types of bony sarcomas.
A team of scientists from the National University of Singapore (NUS) has established novel insights into the relationship between breast cancer tumour intracellular redox environment and the cancer cells' ability to become invasive.
Researchers of the Wihuri Research Institute and the University of Helsinki, Finland, have found that some of the harmful effects of a commonly used cancer drug can be alleviated by using gene therapy that stimulates blood vessel growth in the heart.
Nanomedicine has the potential to help personalize cancer treatments and reduce side effects of therapeutic drugs.
The U.S. Food and Drug Administration today granted accelerated approval to Lartruvo (olaratumab) with doxorubicin to treat adults with certain types of soft tissue sarcoma (STS), which are cancers that develop in muscles, fat, tendons or other soft tissues.
Engineering researchers at The University of Texas at Austin have developed a new method that delivers chemotherapy directly and efficiently to individual cells.